Itraconazole oral solution is indicated:
For the treatment of oral and/or oesophageal candidosis in HIV-positive or other immunocompromised patients.
As prophylaxis of deep fungal infections anticipated to be susceptible to itraconazole, when standard therapy is considered inappropriate, in patients with haematological malignancy or undergoing bone marrow transplant, and who are expected to become neutropenic (ie < 500 cells/µl). At present, there are insufficient clinical efficacy data in the prevention of aspergillosis. Consideration should be given to national and/or local guidance regarding the appropriate use of antifungal agents.
For further information please contact us at firstname.lastname@example.org
Go back to Licensed products full list